Doppler monitoring of preventive migraine treatment
DOI:
https://doi.org/10.12775/JEHS.2025.80.64019Keywords
migraine, transcranial duplex scanning, cerebral hemodynamics, cerebrovascular reactivity, TopiromaxAbstract
The article presents an analysis of literature data and the results of our own clinical and Doppler examination of 116 young patients with migraine. (18-45 years old), a clinical and neurological examination was performed, an assessment of the intensity of the degree of decrease in the patient's functional activity, a study of the state of cerebral arteries and cerebrovascular reactivity using ultrasound Doppler. Cerebral hemodynamics during a migraine attack is characterized by a pattern vasospasm in migraine without aura and a pattern of impaired perfusion in migraine with aura in the middle cerebral arteries, as well as increased perfusion in the cerebral arteries. Hyperreactivity to hypercapnic load and photoreactivity test is a characteristic Doppler pattern in patients with migraine without aura. Hyperreactivity to hyperventilatory load, reflecting a hyperconstrictive vascular response, predominates in migraine with aura. The use of Topiramate for the preventive treatment of migraine in both clinical groups significantly reduces the frequency, duration and intensity of migraine attacks. Under the influence of the drug, a decrease in the frequency, duration and intensity of attacks was observed. The vascular effect of the drug was manifested in a decrease in the initially increased blood flow velocity in the MCA. The drug contributed to the normalization of cerebrovascular hyperreactivity, mainly to the CO2 test in patients with migraine with aura and to the photoreactivity test in patients with migraine without aura.
References
1. Burch RC, Buse DC, Lipton RB. Migraine: Epidemiology, Burden, and Comorbidity. Neurol Clin. 2019; 37(4): 631-649. doi: 10.1016/j.ncl.2019.06.001.
2. Ashina M, Katsarava Z, Do TP, Buse DC, Pozo-Rosich P, Özge A. et al. Migraine: epidemiology and systems of care. Lancet. 2021; 397(10283): 1485-1495. doi: 10.1016/S0140-6736(20)32160-7.
3. Kalashnikov VI, Vastyanov RS, Gozhenko OA, Andreeva TO, Stoyanov OM, Chebotareva HМ. et al. Postisometrical relaxation hemodynamic effects in patients with cervicocranialgia and vestibular dysfunction. Acta Balneologica. 2023. 65(5): 330-335.
4. Smith TR. Epidemiology and impact of headache: an overview. Prim Care. 2004; 31(2): 237-241. doi: 10.1016/j.pop.2004.02.001.
5. Stoyanov AN, Kalashnikov VI, Vastyanov RS, Pulyk AR, Son AS, Kolesnik OO. State of autonomic regulation and cerebrovascular reactivity in patients with headache with arterial hypertension. Wiadomości Lekarskie. 2022; 75 (9, part 2): 2233-2237.
6. Freitag FG. Headache Medicine Grand Challenge: Headache: A New Frontier, A New Challenge. Front Pain Res (Lausanne). 2021; 2: 690683. doi: 10.3389/fpain.2021.690683.
7. Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: Updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021; 61(1): 60-68. doi: 10.1111/head.14024.
8. Fu T, Liu L, Huang X, Zhang D, Gao Y, Yin X. et al. Cerebral blood flow alterations in migraine patients with and without aura: An arterial spin labeling study. J Headache Pain. 2022; 23(1):131. doi: 10.1186/s10194-022-01501-0.
9. Moroz VM, Shandra OA, Vastyanov RS, Yoltukhivsky MV, Omelchenko OD. Physiology. Vinnytsia: Nova Knyha. 2016. 722.
10. Kellner-Weldon F, El-Koussy M, Jung S, Jossen M, Klinger-Gratz PP, Wiest R. Cerebellar hypoperfusion in migraine attack: incident and significance. Am J Neuroradiol. 2018; 39: 435–440. doi: 10.3174/ajnr.A5508
11. Lucas C. Migraine with aura. Rev Neurol (Paris). 2021; 177(7): 779-784. doi: 10.1016/j.neurol.2021.07.010.
12. Shandra AA, Godlevsky LS, Vastyanov RS. Epileptic and antiepileptic systems interrelation as the systemic indicator of the complexity of epileptic activity manifestation. Pan-Brain Abnormal Neural Network in Epilepsy. Feng Ru Tang (Ed.). Singapore: Research Signpost; 2009. 99–120.
13. Khan J, Asoom LIA, Sunni AA, Rafique N, Latif R, Saif SA. et al. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021; 139: 111557. doi: 10.1016/j.biopha.2021.111557.
14. Stoyanov AN, Mashchenko SS, Kalashnikov VI, Vastyanov RS, Pulyk AR, Andreeva TO. et al. Vestibular dysfunctions in chronic brain ischemia in the post COVID period. Wiadomości Lekarskie. 2023; 76(3): 591-596.
15. Stoyanov OM, Kalashnikov VY, Vastyanov RS, Mirdzhuraev EM, Son AS, Fedorenko TV. et al Cerebrovascular disorders in patients with COVID-19 consequences pathogenetically determined diagnosis and methods of correction. World of Medicine and Biology. 2024; 2(88): 146-151.
16. Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A. et al. Migraine. Nat. Rev. Dis Primers. 2022; 8(1): 2. doi: 10.1038/s41572-021-00328-4.
17. Shandra AA, Godlevskii LS, Vastyanov RS, Brusentsov AI, Mikhaleva II, Prudchenko IA, Zaporozhan VN. Effect of intranigral dosage with delta sleep-inducing peptide and its analogs on movement and convulsive activity in rats. Neurosci. Behav. Physiol. 1996; 26(6): 567-571.
18. Shandra AA, Godlevskii LS, Brusentsov AI, Petrashevich VP, Vastyanov RS, Nikel B, Mikhaleva II. Delta-sleep-inducing peptide and its analogs and the serotoninergic system in the development of anticonvulsive influences. Neurosci. Behav. Physiol. 1998; 28(5): 521-526.
19. Headache Classification Committee of International Headache Society (IHS) International Classification of Headache Disorders, 3rd Ed. Cephalalgia. 2018; 38(1): 1-211.
20. Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A. et al. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One. 2015; 10(7): 0130733. doi: 10.1371/journal.pone.0130733.
21. Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action . Neurotherapeutics. 2018; 15: 274-290.
22. Al-Hassany L, Lyons HS, Boucherie DM, Farham F, Lange KS, Marschollek K. et al. The sense of stopping migraine prophylaxis. J Headache Pain. 2023; 24(1): 9. doi: 10.1186/s10194-023-01539-8.
23. Silberstein S, Tfelt -Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J. et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008; 28:484-495. doi:10.1111/j.1468-2982. 2008.01555.x
24. Stoyanov O, Kalashnikov V, Vastyanov R, Son A, Kolesnik O, Oleinik S. Vegetative Disregulation in the Pathogenesis of Cerebral Angiodystonia and Chronic Brain Ischemia. International Neurological Journal. 2022; 18(3): 19-24. doi:10.22141/2224-0713.18.3.2022.941.
25. Stoyanov OM, Vastyanov RS, Myronov OO, Kalashnikov VI, Babienko VV, Hruzevskiy OA. et al. Vegetative system pathogenetic role in chronic brain ischemia, cerebral hemodynamics disorders and autonomous dysregulation. World of Medicine and Biology. 2022; 2(80): 162-168.
26. Mathew NT. Antiepileptic drugs in migraine prevention. Headache. 2001; 41(1): 18-24.
27. Shandra AA, Godlevskii LS, Brusentsov AI, Vastyanov RS, Karlyuga VA, Dzygal AF, Nikel B. Effects of delta-sleep-inducing peptide in cerebral ischemia in rats. Neurosci. Behav. Physiol. 1998; 28(4): 443–446
28. Godlevsky LS, Shandra AA, Mikhaleva II, Vastyanov RS, Mazarati AM. Seizure-protecting effects of kyotorphin and related peptides in animal model of epilepsy. Brain Res. Bull. 1995; 11: 55-57
29. Godlevsky LS, Shandra AA, Oleinik AA, Vastyanov RS, Kostyushov VV, Timschishin OL. TNF- in cerebral cortex and cerebellum is affected by amygdalar kindling but not by stimulation of cerebellum. Polish J Pharmacol. 2002; 54: 655-660.
30. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). Headache. 2015; 21(4): 973-989.
31. Ashina M, Buse DC, Ashina H, Pozo-Rosich P, Peres MFP, Lee MJ. et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021; 397(10283):1505-1518. doi: 10.1016/S0140-6736(20)32342-4.
32. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N. et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007; 47(2):170-180. doi: 10.1111/j.1526-4610.2006. 00684.x.
33. Rossi P, Cesarino F, Faroni J, Malpezzi MG, Sandrini G, Nappi G. SUNCT syndrome successfully treated with topiramate: case reports. Cephalalgia. 2003; 23(10): 998–1000.
34. Andreyeva TO, Stoyanov OM, Chebotaryova GM, Vastyanov RS, Kalashnikov VI, Stoyanov AO. Comparative clinical and morphometric investigations of cervical stenosis of the spinal canal in humans and dogs. Regulatory Mechanisms in Biosystems. 2022; 13(3): 301-307. doi:10.15421/022239
35. Hansen JM, Schankin CJ. Cerebral hemodynamics in the different migraine phases and cluster headache . J Cereb Blood Flow Metab. 2019; 39(4): 595–609.
36. Silvestrini M, Matteis M, Troisi E, Cupini LM, Bernardi G. Cerebrovascular reactivity in migraine with and without aura. Headache 1996; 36(1): 37-40. doi: 10.1046/j.1526-4610.1996.3601037.x.
37. Öztürk B, Karadaş Ö. Cerebral Hemodynamic Changes During Migraine Attacks and After Triptan Treatments. Noro Psychiatrist Ars. 2020; 57(3): 192–196. doi: 10.29399/npa.21650
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 V. Kalashnikov, R. Vastyanov, O. Stoyanov
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 97
Number of citations: 0
